Login / Signup

Phosphatidylserine enriched with polyunsaturated n-3 fatty acid supplementation for Attention-Deficit Hyperactivity Disorder (ADHD) in children & adolescents with epilepsy: a randomized placebo-controlled trial.

Sylvain RheimsVania HerbillonSégolène GaillardCatherine MercierNathalie VilleuveFrédéric VillégaClaude CancesPierre CastelnauSilvia NapuriAnne de Saint-MartinStėphane AuvinSylvie N Guyen The TichPatrick BerquinJulitta de BellecizeMathieu MilhPascal RoyAlexis A ArzimanoglouJacques BodennecLaurent BezinBehrouz Kassainull null
Published in: Epilepsia open (2024)
Our study remaining underpowered, no formal conclusion about the effect of Ps-Omega3 could be drawn. However, our data strongly suggested that the PS-Omega 3 formulation used in the current study did not improve ADHD symptoms in children with epilepsy.
Keyphrases
  • attention deficit hyperactivity disorder
  • autism spectrum disorder
  • fatty acid
  • young adults
  • working memory
  • drug delivery
  • randomized controlled trial
  • machine learning
  • depressive symptoms